Gregg Williams Purchases 1,587,301 Shares of Vivani Medical (NASDAQ:VANI) Stock

Posted by Brenda Bartman on Apr 18th, 2026

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams bought 1,587,301 shares of Vivani Medical stock in a transaction dated Wednesday, April 15th. The stock was acquired at an average price of $1.26 per share, for a total transaction of $1,999,999.26. Following the completion of the acquisition, the director owned 32,944,484 shares in the company, valued at approximately $41,510,049.84. The trade was a 5.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Gregg Williams also recently made the following trade(s):

On Sunday, March 15th, Gregg Williams bought 1,575,231 shares of Vivani Medical stock. The stock was acquired at an average price of $1.07 per share, for a total transaction of $1,685,497.17.
On Tuesday, January 27th, Gregg Williams bought 1,351,351 shares of Vivani Medical stock. The stock was acquired at an average price of $1.48 per share, for a total transaction of $1,999,999.48.

Vivani Medical Stock Up 2.3%

Vivani Medical stock opened at $1.34 on Friday. The company’s 50-day moving average price is $1.16 and its 200-day moving average price is $1.33. Vivani Medical, Inc. has a twelve month low of $0.92 and a twelve month high of $1.92. The company has a market cap of $113.43 million, a PE ratio of -3.12 and a beta of 2.16.

Vivani Medical (NASDAQ:VANI – Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. As a group, sell-side analysts expect that Vivani Medical, Inc. will post -0.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on VANI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, January 9th. HC Wainwright cut their price target on shares of Vivani Medical from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.50.

Check Out Our Latest Stock Analysis on Vivani Medical

Hedge Funds Weigh In On Vivani Medical

Hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL bought a new position in Vivani Medical during the 4th quarter valued at about $1,127,000. Geode Capital Management LLC grew its holdings in Vivani Medical by 29.6% during the 4th quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock valued at $568,000 after purchasing an additional 105,398 shares during the last quarter. State Street Corp grew its holdings in Vivani Medical by 12.5% during the 4th quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after purchasing an additional 16,070 shares during the last quarter. Marshall Wace LLP bought a new position in Vivani Medical during the 4th quarter valued at about $174,000. Finally, Renaissance Technologies LLC grew its holdings in Vivani Medical by 118.4% during the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares during the last quarter. 6.78% of the stock is currently owned by institutional investors.

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.